Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population
J. Floege(Universitätsklinikum Aachen), Guntram Schernthaner(Rudolfinerhaus Hospital), Bruno Fouqueray, David C. Wheeler(University College London), Jae Bum Kim(Lehigh University), Florian Kronenberg(Innsbruck Medical University), Daniele Marcelli(Fresenius Medical Care (Germany)), Tilman B. Drüeke(Inserm), Angel de Francisco(Marqués de Valdecilla University Hospital), Elizabeth Ireland(Amgen (United States)), Charles Chazot(Clinique Charcot), Jutta Passlick‐Deetjen(Fresenius Medical Care (Germany))
Cited by 478
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Next-generation genotype imputation service and methods
|Nature Genetics|2016|4.5k
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
|New England Journal of Medicine|2006|2.1k